Get the Stockscreener App
1.55
3.13%
-0.05
Pds Biotechnology Corporation Stock (PDSB) Latest News
Clinical Trials News Live Feed - StockTitan
PDS Biotech set for Phase 3 trial in HPV-positive cancer treatment - MSN
FDA approves PDS Biotech's Phase 3 trial design for cancer therapy - MSN
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Marketscreener.com
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
PDS Biotech Advances Novel HPV Cancer Treatment to Phase 3 Trial with FDA Fast Track Status | PDSB Stock News - StockTitan
Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance
PDS Biotechnology Corporation (NASDAQ: PDSB): Hidden Gems In A Time Of Volatility - Stocks Register
Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Inspirion Wealth Advisors LLC Sells 270,862 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - MarketBeat
PDSB stock touches 52-week low at $1.51 amid market challenges - Investing.com Nigeria
Spero Therapeutics names Esther Rajavelu as Interim President and CEO (NASDAQ:SPRO) - Seeking Alpha
Geode Capital Management LLC Acquires 37,142 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Ball Co. (NYSE:BALL) Shares Sold by GAMMA Investing LLC - Defense World
PDS Planning Inc Has $23.21 Million Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Meet Gauzy and Research Frontiers at CES This Week to See the Latest in SPD-SmartGlass Products and Technology - Quantisnow
State Street Corp Sells 18,700 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp Announces Pricing Of Public Offering Of About $12 mln Shares - Reuters
PDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC Wainwright - MarketBeat
DBV stock rallies post-market on FDA Viaskin update (NASDAQ:DBVT) - Seeking Alpha
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PDS Biotech Grants Stock Options to New Clinical Employee Under Inducement Plan - StockTitan
PDSBPDS Biotechnology Corporation Latest Stock News & Market Updates - StockTitan
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET - The Manila Times
PDS Biotech Announces Expert Panel on HPV16 Cancer Treatment Phase 3 Trial - StockTitan
A share offer that's hard to refuse - Investors Chronicle
BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors - Newsfile
PreveCeutical Medical Appoints Biopharma Veteran Stephen Glover to BioGene Board - StockTitan
Research Analysts Issue Forecasts for PDSB FY2024 Earnings - Defense World
FY2024 EPS Estimate for PDS Biotechnology Lowered by Analyst - MarketBeat
Kronos Bio stock in focus on CEO change, layoffs (KRON:NASDAQ) - Seeking Alpha
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround - Yahoo Finance
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call Transcript - MSN
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC - OncLive
PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference - StockTitan
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PDS Biotechnology Corporation (PDSB) Quarterly 10-Q Report - Quartzy
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks
Earnings call: PDS Biotech reports progress in HPV cancer trials By Investing.com - Investing.com Canada
Earnings call: PDS Biotech reports progress in HPV cancer trials - Investing.com
PDSB stock touches 52-week low at $2.21 amid market challenges - Investing.com India
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications - MarketWatch
PDS Biotechnology Corporation Provides Clinical Programs Update - Marketscreener.com
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):